Financial Services » Investing & Securities | Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,175.20
14,770.60
14,884.60
39,252.40
21,568.40
52,812.90
Total Accounts Receivable
89.10
277.00
1,051.80
452.70
1,105.80
102.70
Inventories
119.10
372.20
390.90
-
-
-
Other Current Assets
191.60
675.60
367.10
987.00
1,852.70
1,692.10
Total Current Assets
7,575.00
16,095.50
16,694.30
40,692.10
24,526.90
54,607.70
Net Property, Plant & Equipment
1,014.80
1,280.40
2,768.90
4,117.70
12,973.30
15,193.80
Total Investments and Advances
5,105.90
6,886.00
5,379.40
509.40
269.40
240
Intangible Assets
3,901.00
18,835.50
23,627.90
21,771.40
20,098.50
15,649.50
Other Assets
-
587.70
989.90
1,537.90
3,294.10
5,952.20
Total Assets
17,596.70
43,685.10
49,460.40
68,628.50
61,162.30
91,643.10
Accounts Payable
213.90
426.90
260.90
216.20
225.30
Income Tax Payable
-
814.30
-
28.90
28.90
Other Current Liabilities
1,987.80
2,835.10
2,758.40
2,119.00
3,422.00
Total Current Liabilities
2,201.70
4,076.30
3,019.30
2,364.00
3,676.10
Other Liabilities
-
452.70
76.20
370.50
183.70
Total Liabilities
2,201.70
4,529.00
3,095.50
2,734.50
3,859.80
Common Equity (Total)
15,395.10
39,156.10
46,364.90
65,894.00
57,302.50
Total Shareholders' Equity
15,395.10
39,156.10
46,364.90
65,894.00
57,302.50
Total Equity
15,395.10
39,156.10
46,364.90
65,894.00
57,302.50
Liabilities & Shareholders' Equity
17,596.70
43,685.10
49,460.40
68,628.50
61,162.30

About Cellular Biomedicine Group

View Profile
Address
1345 Avenue of Americas
New York New York 10105
United States
Employees -
Website http://www.cellbiomedgroup.com
Updated 07/08/2019
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA. .

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.